Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Inflammatory Bowel Diseases

  Free Subscription


04.03.2024

3 Aliment Pharmacol Ther
1 Am J Gastroenterol
1 BMC Gastroenterol
3 Clin Gastroenterol Hepatol
1 Dig Dis Sci
4 Eur J Gastroenterol Hepatol
2 Gastroenterology
2 Gut
7 Inflamm Bowel Dis
5 J Crohns Colitis
2 Lancet Gastroenterol Hepatol
1 PLoS One
2 Scand J Gastroenterol
1 Z Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. ERIKSSON C, Sun J, Bryder M, Broms G, et al
    Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.
    Aliment Pharmacol Ther. 2024 Feb 29. doi: 10.1111/apt.17932.
    PubMed         Abstract available

  2. VAN LIERE ELSA, de Boer NKH
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024;59:792-793.
    PubMed        

  3. VASUDEVAN A, Con D, van Langenberg DR
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2024;59:794.
    PubMed        


    Am J Gastroenterol

  4. ANDERSON KL, Anand R, Feuerstein JD
    Insurance Companies' Poor Adherence to Guidelines for Moderate to Severe Ulcerative Colitis/Crohn's Disease Management.
    Am J Gastroenterol. 2024 Feb 29. doi: 10.14309/ajg.0000000000002720.
    PubMed         Abstract available


    BMC Gastroenterol

  5. OH DJ, Hwang Y, Kim SH, Nam JH, et al
    Reading of small bowel capsule endoscopy after frame reduction using an artificial intelligence algorithm.
    BMC Gastroenterol. 2024;24:80.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  6. DUAN R, Zhang C, Li G, Li J, et al
    Antibiotic exposure and risk of new-onset inflammatory bowel disease: a systematic review and dose-response meta-analysis.
    Clin Gastroenterol Hepatol. 2024 Feb 27:S1542-3565(24)00218.
    PubMed         Abstract available

  7. GUPTA A, Peyrin-Biroulet L, Ananthakrishnan AN
    Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2024;22:499-512.
    PubMed         Abstract available

  8. BOYD T, Ananthakrishnan AN
    Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States.
    Clin Gastroenterol Hepatol. 2024;22:659-661.
    PubMed         Abstract available


    Dig Dis Sci

  9. KOLOSKI N, Shah A, Kaan I, Ben Jacob R, et al
    Healthcare Utilization Patterns: Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Gastroesophageal Reflux Disease.
    Dig Dis Sci. 2024 Feb 24. doi: 10.1007/s10620-024-08297.
    PubMed         Abstract available


    Eur J Gastroenterol Hepatol

  10. KOSTEV K, Roderburg C, Loosen SH
    Inflammatory bowel disease is associated with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2024;36:498.
    PubMed        

  11. BAI Y, Sun Y, He Q, Bai X, et al
    Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024;36:359-370.
    PubMed         Abstract available

  12. BHAYANA H, Sharma TK, Sharma A, Dhillon MS, et al
    Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Feb 21. doi: 10.1097/MEG.0000000000002735.
    PubMed         Abstract available

  13. D'HAENS G, Baert F, Danese S, Kobayashi T, et al
    Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
    Eur J Gastroenterol Hepatol. 2024;36:404-415.
    PubMed         Abstract available


    Gastroenterology

  14. PEERY AF, Kelly CR, Kao D, Vaughn BP, et al
    AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.
    Gastroenterology. 2024;166:409-434.
    PubMed         Abstract available

  15. DULAI PS, Singh S, Jairath V, Wong E, et al
    Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases.
    Gastroenterology. 2024;166:396-408.
    PubMed         Abstract available


    Gut

  16. ABDELRAHIM M, Siggens K, Iwadate Y, Maeda N, et al
    New AI model for neoplasia detection and characterisation in inflammatory bowel disease.
    Gut. 2024 Feb 23:gutjnl-2023-330718. doi: 10.1136/gutjnl-2023-330718.
    PubMed        

  17. ZHANG L, Agrawal M, Ng SC, Jess T, et al
    Early-life exposures and the microbiome: implications for IBD prevention.
    Gut. 2024;73:541-549.
    PubMed         Abstract available


    Inflamm Bowel Dis

  18. MARTINELLI M, Miele E, Staiano A
    Surgical Complications Need to Be Carefully Excluded Before Ruling Out a Diagnosis of De Novo Crohn's Disease.
    Inflamm Bowel Dis. 2024 Feb 24:izae026. doi: 10.1093.
    PubMed        

  19. QING X, Zhang C, Zhong Z, Zhang T, et al
    Causal Association Analysis of Periodontitis and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study.
    Inflamm Bowel Dis. 2024 Feb 26:izad188. doi: 10.1093.
    PubMed         Abstract available

  20. DALAL RS, Winter RW, Gupta S, Sasson GF, et al
    Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States.
    Inflamm Bowel Dis. 2024 Feb 26:izae038. doi: 10.1093.
    PubMed        

  21. GONG T, Brew BK, Lundholm C, Smew AI, et al
    Comorbidity Between Inflammatory Bowel Disease and Asthma and Allergic Diseases: A Genetically Informed Study.
    Inflamm Bowel Dis. 2024 Feb 27:izae027. doi: 10.1093.
    PubMed         Abstract available

  22. SWAMINATHAN A, Borichevsky GM, Frampton CM, Day AS, et al
    Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Feb 28:izae032. doi: 10.1093.
    PubMed         Abstract available

  23. GREYWOODE R, Nahvi S, Ullman T, Keefer L, et al
    Feasibility and Acceptability of Digital Behavioral Interventions Among Black and Hispanic Patients With Inflammatory Bowel Disease: A Randomized Pilot Study.
    Inflamm Bowel Dis. 2024 Mar 1:izae034. doi: 10.1093.
    PubMed        

  24. OURANOS K, Saleem H, Vassilopoulos S, Vassilopoulos A, et al
    Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2024 Mar 1:izae031. doi: 10.1093.
    PubMed         Abstract available


    J Crohns Colitis

  25. ROSH JR, Turner D, Hyams JS, Dubinsky M, et al
    Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-Onset and Adult-Onset Disease.
    J Crohns Colitis. 2024 Feb 26:jjae030. doi: 10.1093.
    PubMed         Abstract available

  26. TORRES J, Colombel JF, Mary JY
    Lemman Index in Children: Still an Open Question.
    J Crohns Colitis. 2024;18:331-332.
    PubMed        

  27. GEBEYEHU GG, Taylor F, Dobson L, Cummings JRF, et al
    Validation of the IBD-Control Questionnaire across different sociodemographic and clinical subgroups: secondary analysis of a nationwide electronic survey.
    J Crohns Colitis. 2024;18:275-285.
    PubMed         Abstract available

  28. GRANT RK, Jones GR, Plevris N, Lynch RW, et al
    Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset.
    J Crohns Colitis. 2024;18:286-290.
    PubMed         Abstract available

  29. DHALIWAL J, Tertigas D, Carman N, Lawrence S, et al
    Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study.
    J Crohns Colitis. 2024;18:233-245.
    PubMed         Abstract available


    Lancet Gastroenterol Hepatol

  30. NOOR NM, Lee JC, Bond S, Dowling F, et al
    A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034.
    PubMed         Abstract available

  31. CHAPMAN TP, Ahmad T, Satsangi J
    Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
    Lancet Gastroenterol Hepatol. 2024 Feb 22:S2468-1253(23)00406.
    PubMed        


    PLoS One

  32. JAMES JP, Riis LB, Sokilde R, Malham M, et al
    Short noncoding RNAs as predictive biomarkers for the development from inflammatory bowel disease unclassified to Crohn's disease or ulcerative colitis.
    PLoS One. 2024;19:e0297353.
    PubMed         Abstract available


    Scand J Gastroenterol

  33. VIEUJEAN S, Gillard R, Delanaye P, Seidel L, et al
    Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn's disease.
    Scand J Gastroenterol. 2024;59:296-303.
    PubMed         Abstract available

  34. MIDJORD J, Nielsen KR, Vang AG, Strom M, et al
    Risk of malignancy in a high-incidence population-based cohort of Faroese patients with inflammatory bowel disease from 1960 to 2020 - a Faroese IBD cohort study.
    Scand J Gastroenterol. 2024 Feb 26:1-8. doi: 10.1080/00365521.2024.2320712.
    PubMed         Abstract available


    Z Gastroenterol

  35. KOLLECKER T, Nistal M, Waltz V, Ehard F, et al
    [Takayasu arteritis after COVID-19 infection in a 26-year-old female patient with Crohn's disease].
    Z Gastroenterol. 2024 Feb 28. doi: 10.1055/a-2187-9295.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.